{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:24:22Z","timestamp":1786994662650,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008258","name":"Hyundai Hope on Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012893","name":"National Institutes of Health Division of Loan Repayment","doi-asserted-by":"publisher","award":["L40CA231428"],"award-info":[{"award-number":["L40CA231428"]}],"id":[{"id":"10.13039\/100012893","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA170257"],"award-info":[{"award-number":["CA170257"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neo.2025.101215","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T21:02:16Z","timestamp":1754514136000},"page":"101215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["High-dose DFMO alters protein translation in neuroblastoma"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7683","authenticated-orcid":false,"given":"Andrea T.","family":"Franson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-5318","authenticated-orcid":false,"given":"Rohan","family":"Vemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Scadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-4852","authenticated-orcid":false,"given":"Michael D.","family":"Hogarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9579","key":"10.1016\/j.neo.2025.101215_bib0001","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.neo.2025.101215_bib0002","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"4653","key":"10.1016\/j.neo.2025.101215_bib0003","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1126\/science.6719137","article-title":"Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage","volume":"224","author":"Brodeur","year":"1984","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.neo.2025.101215_bib0004","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.ejca.2004.07.025","article-title":"MYCN amplification remains prognostically strong 20 years after its \"clinical debut\"","volume":"40","author":"Cohn","year":"2004","journal-title":"Eur J Cancer"},{"issue":"37","key":"10.1016\/j.neo.2025.101215_bib0005","doi-asserted-by":"crossref","first-page":"14094","DOI":"10.1073\/pnas.0804455105","article-title":"High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma","volume":"105","author":"Fredlund","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.neo.2025.101215_bib0006","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1186\/gb-2008-9-10-r150","article-title":"Distinct transcriptional MYCN\/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas","volume":"9","author":"Westermann","year":"2008","journal-title":"Genome Biol"},{"issue":"3","key":"10.1016\/j.neo.2025.101215_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-17-0993","article-title":"MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification","volume":"8","author":"Zimmerman","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.neo.2025.101215_bib0008","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/emboj\/20.6.1383","article-title":"N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis","volume":"20","author":"Boon","year":"2001","journal-title":"Embo Journal"},{"issue":"9","key":"10.1016\/j.neo.2025.101215_bib0009","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1101\/gad.1067003","article-title":"Genomic targets of the human c-myc protein","volume":"17","author":"Fernandez","year":"2003","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/pr900701v","article-title":"Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma","volume":"9","author":"Chen","year":"2010","journal-title":"J Proteome Res"},{"issue":"10","key":"10.1016\/j.neo.2025.101215_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026057","article-title":"Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation","volume":"6","author":"Ji","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neo.2025.101215_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"van Riggelen","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"29","key":"10.1016\/j.neo.2025.101215_bib0013","doi-asserted-by":"crossref","first-page":"14904","DOI":"10.1074\/jbc.R116.731661","article-title":"Functions of polyamines in mammals","volume":"291","author":"Pegg","year":"2016","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.neo.2025.101215_bib0014","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1158\/1078-0432.CCR-08-3213","article-title":"Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma","volume":"15","author":"Evageliou","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2025.101215_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fonc.2012.00162","article-title":"Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma","volume":"2","author":"Gamble","year":"2012","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.neo.2025.101215_bib0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/PL00000852","article-title":"Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications","volume":"58","author":"Thomas","year":"2001","journal-title":"Cell Mol Life Sci"},{"issue":"34","key":"10.1016\/j.neo.2025.101215_bib0017","doi-asserted-by":"crossref","first-page":"20874","DOI":"10.1016\/S0021-9258(17)45297-5","article-title":"A 13C NMR study of [5,8-13C2]spermidine binding to tRNA and to Escherichia coli macromolecules","volume":"265","author":"Frydman","year":"1990","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.neo.2025.101215_bib0018","doi-asserted-by":"crossref","first-page":"11275","DOI":"10.1093\/nar\/gku837","article-title":"Endogenous polyamine function\u2013the RNA perspective","volume":"42","author":"Lightfoot","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.neo.2025.101215_bib0019","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/10409238.2014.939608","article-title":"The hypusine-containing translation factor eIF5A","volume":"49","author":"Dever","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.neo.2025.101215_bib0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/2643-3230.BCD-22-0162","article-title":"The polyamine-hypusine circuit controls an oncogenic translational program essential for malignant conversion in MYC-driven lymphoma","volume":"4","author":"Nakanishi","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"16","key":"10.1016\/j.neo.2025.101215_bib0021","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1073\/pnas.90.16.7804","article-title":"The ornithine decarboxylase gene is a transcriptional target of c-myc","volume":"90","author":"Bello-Fernandez","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"477","key":"10.1016\/j.neo.2025.101215_bib0022","first-page":"11","article-title":"Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma","author":"Gamble","year":"2019","journal-title":"Sci Transl Med"},{"issue":"6402","key":"10.1016\/j.neo.2025.101215_bib0023","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/360355a0","article-title":"Ornithine decarboxylase activity is critical for cell transformation","volume":"360","author":"Auvinen","year":"1992","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0024","first-page":"2618","article-title":"Transformation of NIH\/3T3 cells by ornithine decarboxylase overexpression","volume":"53","author":"Moshier","year":"1993","journal-title":"Cancer Research"},{"issue":"7365","key":"10.1016\/j.neo.2025.101215_bib0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature10393","article-title":"Polyamine sensing by nascent ornithine decarboxylase antizyme stimulates decoding of its mRNA","volume":"477","author":"Kurian","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0026","doi-asserted-by":"crossref","first-page":"eaar2606","DOI":"10.1126\/sciadv.aar2606","article-title":"Oil for the cancer engine: the cross-talk between oncogenic signaling and polyamine metabolism","volume":"4","author":"Arruabarrena-Aristorena","year":"2018","journal-title":"Sci Adv"},{"issue":"23","key":"10.1016\/j.neo.2025.101215_bib0027","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.neo.2025.101215_bib0028","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/jnci\/djy022","article-title":"Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients","volume":"110","author":"Depuydt","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.neo.2025.101215_bib0029","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ijc.25074","article-title":"The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification","volume":"126","author":"Geerts","year":"2010","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00873231","article-title":"Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy","volume":"12","author":"Ganju","year":"1994","journal-title":"Investigational New Drugs"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0031","first-page":"3438","article-title":"Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients","volume":"5","author":"O'Shaughnessy","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2025.101215_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-023-02525-2","article-title":"Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial","author":"Hogarty","year":"2024","journal-title":"Br J Cancer"},{"issue":"S22","key":"10.1016\/j.neo.2025.101215_bib0033","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jcb.240590816","article-title":"Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer","volume":"59","author":"Meyskens","year":"1995","journal-title":"Journal of Cellular Biochemistry"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0034","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/ijc.33044","article-title":"A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma","volume":"147","author":"Lewis","year":"2020","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.neo.2025.101215_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127246","article-title":"A phase I trial of DFMO targeting polyamine addiction in patients with relapsed\/refractory neuroblastoma","volume":"10","author":"Saulnier Sholler","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32659-w","article-title":"Maintenance DFMO increases survival in high risk neuroblastoma","volume":"8","author":"Sholler","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0037","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.22.02875","article-title":"Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons","volume":"42","author":"Oesterheld","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neo.2025.101215_bib0038","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/0008-5472.CAN-08-2968","article-title":"Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma","volume":"69","author":"Rounbehler","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.neo.2025.101215_bib0039","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat Genet"},{"issue":"7547","key":"10.1016\/j.neo.2025.101215_bib0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(68)90303-6","article-title":"Isoelectric focusing in polyacrylamide gels","volume":"1","author":"Dale","year":"1968","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0041","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/emboj\/16.11.2985","article-title":"Targeted expression of MYCN causes neuroblastoma in transgenic mice","volume":"16","author":"Weiss","year":"1997","journal-title":"Embo Journal"},{"issue":"29","key":"10.1016\/j.neo.2025.101215_bib0042","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1200\/JCO.21.00278","article-title":"Revised Neuroblastoma Risk Classification System: a report from the children's oncology group","volume":"39","author":"Irwin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.neo.2025.101215_bib0043","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.21.00086","article-title":"Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma study group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)","volume":"39","author":"Bellini","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7215","key":"10.1016\/j.neo.2025.101215_bib0044","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Mosse","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neo.2025.101215_bib0045","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41416-023-02208-y","article-title":"Genomic ALK alterations in primary and relapsed neuroblastoma","volume":"128","author":"Rosswog","year":"2023","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.neo.2025.101215_bib0046","first-page":"1583","article-title":"Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group","volume":"12","author":"George","year":"1996","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.neo.2025.101215_bib0047","first-page":"1117","article-title":"Amplification of N-myc and ornithine decarboxylase genes in human neuroblastoma and hydroxyurea-resistant hamster cell lines","volume":"4","author":"Tonin","year":"1989","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.neo.2025.101215_bib0048","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2460\/javma.2001.218.669","article-title":"2000 Report of the AVMA Panel on Euthanasia","volume":"218","year":"2001","journal-title":"Journal of the American Veterinary Medical Association"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0049","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1038\/s41467-020-19452-y","article-title":"Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma","volume":"11","author":"Helmsauer","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neo.2025.101215_bib0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nature Genetics"},{"key":"10.1016\/j.neo.2025.101215_bib0051","first-page":"4248","article-title":"Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients","volume":"47","author":"Brodeur","year":"1987","journal-title":"Cancer Research"},{"key":"10.1016\/j.neo.2025.101215_bib0052","unstructured":"DepMap, Broad. 2023. DepMap 23Q4 public. Figshare+. Dataset. https:\/\/doi.org\/10.25452\/figshare.plus.24667905.v2."},{"issue":"21","key":"10.1016\/j.neo.2025.101215_bib0053","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.4161\/cc.10.21.17973","article-title":"Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression","volume":"10","author":"Carr-Wilkinson","year":"2011","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0054","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41467-017-00408-8","article-title":"Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk","volume":"8","author":"Chang","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.neo.2025.101215_bib0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.1981.150","article-title":"Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase","volume":"30","author":"Haegele","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.neo.2025.101215_bib0056","first-page":"235","article-title":"Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial","volume":"2","author":"Pendyala","year":"1993","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.neo.2025.101215_bib0057","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.1984.2.2.124","article-title":"Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine\u2013an inhibitor of polyamine biosynthesis","volume":"2","author":"Abeloff","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0058","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/emboj\/16.11.2985","article-title":"Targeted expression of NMYC causes neuroblastoma in transgenic mice","volume":"16","author":"Weiss","year":"1997","journal-title":"The EMBO Journal"},{"issue":"17","key":"10.1016\/j.neo.2025.101215_bib0059","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-2539","article-title":"Polyamine antagonist therapies inhibit neuroblastoma initiation and progression","volume":"22","author":"Evageliou","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.neo.2025.101215_bib0060","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.neo.2025.101215_bib0061","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(80)90342-8","article-title":"Inhibition of murine embryonic development by alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase","volume":"65","author":"Fozard","year":"1980","journal-title":"Eur J Pharmacol"},{"issue":"4443","key":"10.1016\/j.neo.2025.101215_bib0062","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.6768132","article-title":"l-ornithine decarboxylase:an essential role in early mammalian embryogenesis","volume":"208","author":"Fozard","year":"1980","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neo.2025.101215_bib0063","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"issue":"14","key":"10.1016\/j.neo.2025.101215_bib0064","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1016\/S0021-9258(19)41234-9","article-title":"Enhanced differential synthesis of proteins in a mammalian cell-free system by addition of polyamines","volume":"250","author":"Atkins","year":"1975","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.neo.2025.101215_bib0065","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1073\/pnas.1219002110","article-title":"Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells","volume":"110","author":"Mandal","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"48","key":"10.1016\/j.neo.2025.101215_bib0066","doi-asserted-by":"crossref","first-page":"18719","DOI":"10.1074\/jbc.TM118.003338","article-title":"Roles of polyamines in translation","volume":"293","author":"Dever","year":"2018","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.neo.2025.101215_bib0067","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1074\/jbc.M110.106419","article-title":"The role of polyamines in supporting growth of mammalian cells is mediated through their requirement for translation initiation and elongation","volume":"285","author":"Landau","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0068","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molcel.2013.04.021","article-title":"eIF5A promotes translation of polyproline motifs","volume":"51","author":"Gutierrez","year":"2013","journal-title":"Molecular Cell"},{"issue":"7243","key":"10.1016\/j.neo.2025.101215_bib0069","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature08034","article-title":"Hypusine-containing protein eIF5A promotes translation elongation","volume":"459","author":"Saini","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neo.2025.101215_bib0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molcel.2017.03.003","article-title":"eIF5A Functions globally in translation elongation and termination","volume":"66","author":"Schuller","year":"2017","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.neo.2025.101215_bib0071","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nmeth.1314","article-title":"SUnSET, a nonradioactive method to monitor protein synthesis","volume":"6","author":"Schmidt","year":"2009","journal-title":"Nat Methods"},{"issue":"21","key":"10.1016\/j.neo.2025.101215_bib0072","doi-asserted-by":"crossref","first-page":"14529","DOI":"10.1074\/jbc.R500031200","article-title":"Regulation of ornithine decarboxylase","volume":"281","author":"Pegg","year":"2006","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0073","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ccell.2018.11.009","article-title":"The roles of initiating truncal mutations in Human cancers: the order of mutations and tumor cell type matters","volume":"35","author":"Levine","year":"2019","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.neo.2025.101215_bib0074","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ccr.2005.03.036","article-title":"Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation","volume":"7","author":"Nilsson","year":"2005","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1916063","article-title":"Eflornithine plus Sulindac for prevention of progression in familial adenomatous polyposis","volume":"383","author":"Burke","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2025.101215_bib0076","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prevention Research"},{"issue":"3","key":"10.1016\/j.neo.2025.101215_bib0077","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/iub.1363","article-title":"Modulation of protein synthesis by polyamines","volume":"67","author":"Igarashi","year":"2015","journal-title":"IUBMB Life"},{"issue":"11","key":"10.1016\/j.neo.2025.101215_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111800","article-title":"Genome-wide analyses and functional classification of proline repeat-rich proteins: potential role of eIF5A in eukaryotic evolution","volume":"9","author":"Mandal","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neo.2025.101215_bib0079","doi-asserted-by":"crossref","first-page":"e7207","DOI":"10.1002\/cam4.7207","article-title":"DFMO inhibition of neuroblastoma tumorigenesis","volume":"13","author":"Gandra","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.neo.2025.101215_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09564-0","article-title":"Reprogramming neuroblastoma by diet-enhanced polyamine depletion","author":"Cherkaoui","year":"2025","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.neo.2025.101215_bib0081","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/gcc.20376","article-title":"Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome","volume":"45","author":"Spitz","year":"2006","journal-title":"Genes, Chromosomes and Cancer"},{"issue":"53","key":"10.1016\/j.neo.2025.101215_bib0082","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1038\/sj.onc.1210552","article-title":"Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data","volume":"26","author":"\u0141astowska","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.neo.2025.101215_bib0083","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ng.2493","article-title":"Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma","volume":"45","author":"Sausen","year":"2013","journal-title":"Nature Genetics"},{"issue":"7","key":"10.1016\/j.neo.2025.101215_bib0084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101990","article-title":"Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN","volume":"9","author":"Guimier","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neo.2025.101215_bib0085","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"23","key":"10.1016\/j.neo.2025.101215_bib0086","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"issue":"269","key":"10.1016\/j.neo.2025.101215_bib0087","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:20:05Z","timestamp":1772007605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":87,"alternative-id":["S1476558625000946"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101215","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.23.634327","asserted-by":"object"}]},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose DFMO alters protein translation in neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101215"}}